Biotech Startups

Cyrano Therapeutics is a clinical-stage regenerative medicine company developing CYR-064, a nasal therapy for post-viral smell loss (hyposmia) and associated loss of taste. It serves patients with anosmia and is advancing its lead candidate through clinical trials toward Phase 3.

3 investors

Cytek Biosciences develops high-parametric analytical instruments and software that enable scientists at pharmaceutical companies, contract research organizations, and academic institutions to generate and analyze biological datasets. The company serves the life sciences research and drug development sectors.

3 investors

Cytofacto appears to be a Japanese startup involved in cell therapy / regenerative medicine, engaging in contract manufacturing of cell-based products (e.g. an agreement regarding manufacturing of "Stemchymal"). The page does not provide a full description of the company's offerings.

3 investors

CytoGen Lab develops liquid biopsy technology for cancer detection through circulating tumor cell (CTC) isolation from blood samples, combining biotechnology and engineering for precision medicine applications.

3 investors

Cytosolix uses its Tumor Activated Permeability (TAP) platform to redesign small molecule oncology drugs into weakly-acidic derivatives that exploit tumor acidity to selectively target and accumulate in solid tumors while sparing healthy tissue. Based on research from Yale University, its pipeline includes an androgen receptor inhibitor for early-stage prostate cancer and additional inhibitors for breast and other cancers.

3 investors

Cytotronics develops Pixel, a semiconductor-to-live-cell interface platform that measures cell viability, morphology, electrophysiology, and metabolism at single-cell resolution across any cell type or 3D organoid system. It serves cell biologists working in therapeutic areas such as vascular biology, stem cell differentiation, cardiovascular and neurological disease, and oncology.

3 investors

D-NOME develops molecular reagent technologies aimed at making diagnostics more affordable and accessible. Founded in 2021, the company builds bio-technologies for the diagnostics and healthcare sector.

3 investors

Daisy Lab is a New Zealand company using precision fermentation to produce dairy products without cows, aiming to reduce the environmental impact of traditional dairy farming. It targets the food production and alternative dairy market by applying New Zealand's dairy processing and food manufacturing expertise.

3 investors

DBV Technologies develops the VIASKIN® patch, a non-invasive, skin-based immunotherapy technology for treating food allergies and other immunological disorders. The company is investigating applications including allergy treatment and vaccine delivery through epicutaneous immunotherapy.

3 investors

Decade develops targeted cancer therapies using AI and high-throughput data analysis to match treatments to individual patients' tumor molecular profiles.

3 investors

Decade Energy provides electrification solutions for mobility and fleet depots, including grid upgrades, battery storage, charging infrastructure, and energy optimization software. It focuses on securing long-term grid capacity for electric truck and fleet depots across Europe.

3 investors

Deep Blue Biotech develops sustainable chemicals by re-engineering cyanobacteria to convert CO₂ into high-value molecules, using AI-driven metabolic modelling. Its products include an ocean-derived hyaluronic acid, targeting the cosmetics/ingredients and broader chemicals industry.

3 investors

Paradigm Health combines technology and services to re-engineer clinical trials, integrating with healthcare provider organizations to improve patient enrollment and access to care. It serves providers and sponsors involved in developing and delivering therapies through clinical trials.

3 investors

Deep Longevity develops AI-powered aging clocks and health analytics tools that estimate biological age and predict long-term health risks using multi-omics data. The company serves healthcare providers, insurers, employers, and wellness platforms seeking to enable preventive, personalized care at scale.

3 investors

DeepMirror develops AI software for hit-to-candidate molecule design in drug discovery, enabling teams to generate novel chemical candidates and predict molecular properties using proprietary data while maintaining strict data privacy and IP security.

3 investors

Deep Root Biolabs develops a biomolecule delivery solution that enhances plants to extract pollutants from soil and concentrate critical minerals, serving agriculture, mineral reclamation, and remediation applications. The technology uses plant-based biomolecules as a non-GMO approach to improve plant performance for environmental and agricultural purposes.

3 investors

DeepSeq designs biologic drugs using AI trained on massive datasets of real protein interactions, predicting properties such as affinity, specificity, immunogenicity, pharmacokinetics, and manufacturability. It aims to accelerate the development of better biologic therapeutics for patients.

3 investors

3 investors

Delee is a medical device company that makes a blood-testing device for early cancer diagnosis and treatment monitoring by isolating and analyzing circulating tumor cells.

3 investors

Delfa provides an AI-driven platform for clinical trial patient recruitment, centralizing calls, notes, and updates while automating repetitive tasks for clinical research site teams. It syncs recruitment data to a site's CTMS and applies agent operating procedures and human review to maintain safety and quality.

3 investors

Delphia Therapeutics is a biotechnology company developing cancer medicines based on its activation lethality platform, aiming to create therapies effective on their own while combating resistance to targeted therapies. It focuses on oncology drug discovery and clinical development.

3 investors

Delpor develops subcutaneous implant devices that deliver therapeutic drugs over extended periods (6-12 months) for chronic condition treatment. The company's passive implant technology enables sustained-release drug delivery through simple in-office procedures, targeting improved patient adherence and consistent pharmacokinetic profiles.

3 investors

Enables people to live more deliberate lives through data-driven insights

3 investors

Dendreon develops and manufactures cellular immunotherapies, including PROVENGE (sipuleucel-T), an FDA-approved cellular immunotherapy for prostate cancer patients. The company also provides cell therapy research, development, and contract manufacturing services to other companies bringing cellular therapies to market.

3 investors